Pitavastatin - pharmacological profile from early phase studies

Atherosclerosis Supplements

Volumn 11, Issue 3, 2010, Pages 3-7

  Catapano, Alberico L ^a  

^a UNIVERSITY OF MILAN   (Italy)

Author keywords

Drug drug interactions; Dyslipidaemia; Hypercholesterolaemia; Pitavastatin; Statins

Indexed keywords

APOLIPOPROTEIN A1; CYTOCHROME P450 2C9; CYTOCHROME P450 3A4; GLYCOPROTEIN P; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPOPROTEIN LIPASE; PITAVASTATIN; PROTEIN; PROTEIN OATP1B1; UNCLASSIFIED DRUG;

ARTICLE; CLINICAL TRIAL (TOPIC); DRUG BIOAVAILABILITY; DRUG DISPOSITION; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; DYSLIPIDEMIA; FOOD; FOOD DRUG INTERACTION; HUMAN; POLYPHARMACY; PRIORITY JOURNAL; UNSPECIFIED SIDE EFFECT;

DRUG INTERACTIONS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; QUINOLINES;

EID: 78650553915     PISSN: 15675688     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1567-5688(10)71063-1     Document Type: Article

References (41)

1. Saito Y Critical appraisal of the role of pitavastatin in treating dyslipidemias and achieving lipid goals. Vasc Health Risk Manag 2009, 5:921-936.
2. Mukhtar RY, Reid J, Reckless JP Pitavastatin. Int J Clin Pract 2005, 59:239-252.
3. Aoki T, Nishimura H, Nakagawa S, et al. Pharmacological profile of a novel synthetic inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme A reductase. Arzneimittelforschung 1997, 47:904-909.
4. Morikawa S, Umetani M, Nakagawa S, et al. Relative induction of mRNA for HMG CoA reductase and LDL receptor by five different HMG-CoA reductase inhibitors in cultured human cells. J Atheroscler Thromb 2000, 7:138-144.
5. Corsini A, Bellosta S, Baetta R, Fumagalli R, Paoletti R, Bernini F New insights into the pharmacodynamic and pharmacokinetic properties of statins. Pharmacol Ther 1999, 84:413-428.
6. Tamaki T, Nakagawa S, Tanabe S Effect of NK-104 on lipid metabolism in HepG2 vcells: inhibition of cholesterol synthesis and enhancement of LDL receptor activity 1994, Kowa Company Ltd., Tokyo, Japan, R99045, 1-1-2010. Tokyo Research Laboratories (Ed.).
7. Budinski D, Arneson V, Hounslow N, Gratsiansky N Pitavastatin compared with atorvastatin in primary hypercholesterolemia or combined dyslipidemia. Clin Lipidol 2009, 4:291-302.
8. Study of pitavastatin 4mg vs. simvastatin 40 mg (following up-titration) in patients with primary hypercholesterolemia or combined dyslipidemia and 2 or more risk factors for coronary heart disease. NK-104-304 clinical study report. Data on file (Kowa).
9. Ose L, Budinski D, Hounslow N, Arneson V Comparison of pitavastatin with simvastatin in primary hypercholesterolaemia or combined dyslipidaemia. Curr Med Res Opin 2009, 25:2755-2764.
10. Ose L, Budinski D, Hounslow N, Arneson V Long-term treatment with pitavastatin is effective and well tolerated by patients with primary hypercholesterolemia or combined dyslipidemia. Atherosclerosis 2010, 210:202-208.
11. Hounslow N, Budinski D, Eriksson M. Pitavastatin 4 mg shows comparable LDL-C and superior triglyceride reduction to simvastatin 40mg in high-risk primary hypercholesterolemia or combined dyslipidaemia. EAS 2010 (poster).
12. Stender S, Hounslow N Robust efficacy of pitavastatin and comparable safety to pravastatin. Atheroscler Suppl 2009, 10:P770.
13. Yokote K, Bujo H, Hanaoka H, et al. Multicenter collaborative randomized parallel group comparative study of pitavastatin and atorvastatin in Japanese hypercholesterolemic patients: collaborative study on hypercholesterolemia drug intervention and their benefits for atherosclerosis prevention (CHIBA study). Atherosclerosis 2008, 201:345-352.
14. Sasaki J, Ikeda Y, Kuribayashi T, et al. A 52-week, randomized, open-label, parallel-group comparison of the tolerability and effects of pitavastatin and atorvastatin on high-density lipoprotein cholesterol levels and glucose metabolism in Japanese patients with elevated levels of low-density lipoprotein cholesterol and glucose intolerance. Clin Ther 2008, 30:1089-1101.
15. Kurihara Y, Douzono T, Kawakita K, Nagasaka Y A large-scale, long-term prospective post-marketing surveillance of pitavastatin (Livalo) - Livalo effectiveness and safety study (LIVES). Jpn Pharmacol Ther 2008, 36:709-731.
16. Betteridge J Pitavastatin - results from phase III & IV. Atheroscl Suppl 2010, 11(3):8-14.
17. Ooyen C, Zecca A, Bersino AM, Catapano AL NK-104, a potent 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, decreases apolipoprotein B-100 secretion from Hep G2 cells. Atherosclerosis 1999, 145:87-95.
18. Pitavastatin. Itavastatin, Nisvastatin, Nk 104, Nks 104, P 872441. Drugs R D 2002, 3:58-60.
19. Saiki A, Murano T, Watanabe F, Oyama T, Miyashita Y, Shirai K Pitavastatin enhanced lipoprotein lipase expression in 3T3-L1 preadipocytes. J Atheroscler Thromb 2005, 12:163-168.
20. Maejima T, Yamazaki H, Aoki T, et al. Effect of pitavastatin on apolipoprotein A-I production in HepG2 cell. Biochem Biophys Res Commun 2004, 324:835-839.
21. Barter P, Gotto AM, LaRosa JC, et al. HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events. N Engl J Med 2007, 357:1301-1310.
22. Teramoto T, Shimano H, Yokote K, Urashima M Effects of pitavastatin (LIVALO Tablet) on high density lipoprotein cholesterol (HDL-C) in hypercholesterolemia. J Atheroscler Thromb 2009, 16:654-661.
23. Goldenberg I, Boyko V, Tennenbaum A, Tanne D, Behar S, Guetta V Long-term benefit of high-density lipoprotein cholesterol-raising therapy with bezafibrate: 16-year mortality follow-up of the bezafibrate infarction prevention trial. Arch Intern Med 2009, 169:508-514.
24. Neuvonen PJ, Niemi M, Backman JT Drug interactions with lipid-lowering drugs: mechanisms and clinical relevance. Clin Pharmacol Ther 2006, 80:565-581.
25. Fujino H, Yamada I, Shimada S, Nagao T, Yoneda M Metabolic fate of pitavastatin (NK-104), a new inhibitor of 3-hydroxy-3-methyl-glutaryl coenzyme A reductase. Effects on drug-metabolizing systems in rats and humans. Arzneimittelforschung 2002, 52:745-753.
26. Fujino H, Yamada I, Shimada S, Yoneda M, Kojima J Metabolic fate of pitavastatin, a new inhibitor of HMG-CoA reductase: human UDP-glucuronosyltransferase enzymes involved in lactonization. Xenobiotica 2003, 33:27-41.
27. Fujino H, Saito S, Tsunenari Y, Kojima J, Sakaeda T Metabolic properties of the acid and lactone forms of HMG-CoA reductase inhibitors. Xenobiotica 2004, 34:961-971.
28. Hirano M, Maeda K, Shitara Y, Sugiyama Y Contribution of OATP2 (OATP1B1) and OATP8 (OATP1B3) to the hepatic uptake of pitavastatin in humans. J Pharmacol Exp Ther 2004, 311:139-146.
29. Hirano M, Maeda K, Matsushima S, Nozaki Y, Kusuhara H, Sugiyama Y Involvement of BCRP (ABCG2) in the biliary excretion of pitavastatin. Mol Pharmacol 2005, 68:800-807.
30. Ose L Pitavastatin: A distinctive lipid lowering drug. Clin Lipidol 2010, 5(3):309-323.
31. NK-104 Pitavastatin Investigators' Brochure 2007, Kowa Company, Ltd., Tokyo, Japan.
32. Williams D, Feely J Pharmacokinetic-pharmacodynamic drug interactions with HMG-CoA reductase inhibitors. Clin Pharmacokinet 2002, 41:343-370.
33. Evans M, Rees A Effects of HMG-CoA reductase inhibitors on skeletal muscle: are all statins the same?. Drug Saf 2002, 25:649-663.
34. Inagaki Y, Hunt T, Arana B, Gosho M, Morgan R Drug-drug interaction study to assess the effects of multiple dose of pitavastatin on steady state warfarin in healthy adult volunteers. Atheroscler 2009, 10(Suppl):e806.
35. Mathew P, Cuddy T, Tracewell WG, Salazar D An open-label study on the pharmacokinetics (PK) of pitavastatin (NK-104) when administered concomitantly with fenofibrate or gemfibrozil in healthy volunteers. Clin Pharmacol Ther 2004, 75:P33.
36. Ando H, Tsuruoka S, Yanagihara H, et al. Effects of grapefruit juice on the pharmacokinetics of pitavastatin and atorvastatin. Br J Clin Pharmacol 2005, 60:494-497.
37. Fujino H, Saito T, Ogawa S, Kojima J Transporter-mediated influx and efflux mechanisms of pitavastatin, a new inhibitor of HMG-CoA reductase. J Pharm Pharmacol 2005, 57:1305-1311.
38. Bizzaro N, Bagolin E, Milani L, Cereser C, Finco B Massive rhabdomyolysis and simvastatin. Clin Chem 1992, 38:1504.
39. Boyd RA, Stern RH, Stewart BH, et al. Atorvastatin coadministration may increase digoxin concentrations by inhibition of intestinal P-glycoprotein-mediated secretion. J Clin Pharmacol 2000, 40:91-98.
40. Hasunuma T, Masahiko N, Takashi Y, et al. The drug-drug Interactions of pitavastatin (NK-104), a novel HMG-CoA reductase Inhibitor and cyclosporine. J Clin Ther Med 2003, 19:381-389.
41. Shitara Y, Hirano M, Sato H, Sugiyama Y Gemfibrozil and its glucuronide inhibit the organic anion transporting polypeptide 2 (OATP2/OATP1B1:SLC21A6)-mediated hepatic uptake and CYP2C8-mediated metabolism of cerivastatin: analysis of the mechanism of the clinically relevant drug-drug interaction between cerivastatin and gemfibrozil. J Pharmacol Exp Ther 2004, 311:228-236.